Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30107
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNguyen, Phillip C-
dc.contributor.authorDonati, Vanessa-
dc.contributor.authorVassili, Catherine-
dc.contributor.authorGrigg, Andrew P-
dc.contributor.authorTiong, Ing S-
dc.date2022-03-27-
dc.date.accessioned2022-06-23T00:22:58Z-
dc.date.available2022-06-23T00:22:58Z-
dc.date.issued2022-05-
dc.identifier.citationLeukemia Research 2022; 116: 106837en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30107-
dc.language.isoeng
dc.subjectAMLen
dc.subjectTolerabilityen
dc.subjectToxicityen
dc.subjectVenetoclaxen
dc.titleReal-world tolerability of venetoclax-based maintenance therapy with azole antifungal prophylaxis for acute myeloid leukemia in remission.en
dc.typeJournal Articleen
dc.identifier.journaltitleLeukemia Researchen
dc.identifier.affiliationOlivia Newton-John Cancer Research Instituteen
dc.identifier.affiliationClinical Haematologyen
dc.identifier.affiliationDepartment of Clinical Hematology, Alfred Hospital and Monash University, Melbourne, Australiaen
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35400541/en
dc.identifier.doi10.1016/j.leukres.2022.106837en
dc.type.contentTexten
dc.identifier.orcid0000-0001-5743-3171en
dc.identifier.orcid0000-0001-7417-4343en
dc.identifier.pubmedid35400541
local.name.researcherGrigg, Andrew P
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.openairetypeJournal Article-
item.grantfulltextnone-
item.languageiso639-1en-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
crisitem.author.deptClinical Haematology-
crisitem.author.deptClinical Haematology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

36
checked on Jan 2, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.